IRCT20200204046377N1
Recruiting
Phase 3
Efficacy and safety of Aprepitant in prevention of chemotherapy induced nausea and vomiting in oncologic patients of Mofid children’s hospital
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Malignant cancer.
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age between 6 month to 17 years
- •Proven malignancy
- •Chemotherapy regimen with moderate to severe nausea
- •Lack of nausea and vomiting 24 hours before starting chemotherapy
- •Lack of known long QT syndrome
- •Lack of abdominal and pelvic radiation therapy over the past week
- •No active infection or any uncontrolled disease associated with malignancy
- •Absence of corticosteroids starting 72 hours prior to chemotherapy for any reason
- •Lack of Benzodiazepine or opioid for 48 hours
Exclusion Criteria
- •Sensitivity to the drugs used
- •Dissatisfaction
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
The safety and efficacy of Aprepitant to the prevention of chemotherapy-induced nausea and vomitingIRCT20200819048455N1Iran University of Medical Sciences85
Recruiting
Not Applicable
Efficacy and safety of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with hematological malignancies after highly emetogenic chemotherapyhematological malignanciesJPRN-UMIN000005624Tokushima University Hospital100
Recruiting
Phase 1
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting after bariatric surgery.Postoperative nausea and vomitingTherapeutic area: Diseases [C] - Digestive System Diseases [C06]CTIS2023-508849-40-00niversity Of Tartu260
Active, not recruiting
Not Applicable
Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer - EMEND_GIChemotherapy-induced nasuea and vomiting (CINV)EUCTR2004-003783-30-DETechnical Unversity of Munich
Active, not recruiting
Phase 1
Aprepitant – effect and safety in treatment of atopic dermatitisAtopic DermatitisTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2013-002029-40-SEKarolinska Institutet50